Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor

• Other Authors: Holzmann, Klaus (Editor), Marian, Brigitte (Editor)
• Format: Electronic Book Chapter
• Language: English
• Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Subjects: Medicine; FGFR4; FGF19; gene regulation; cancer signaling; anticancer; FRS2; FGFR; NVP-BGJ398; LY2874455; sarcoma; cancer-associated fibroblasts; GPER; breast cancer; estrogen; FGFR1; FGF2; optogenetics; ERK; AKT; receptor kinase; neurite outgrowth; HEK293; PC12; fibroblast growth factor receptors; signaling; receptor cross-talk; coreceptor; membrane proteins; FGFR2; ERK1/2; phosphorylation; serine; negative feedback loop; cancer; prognosis; HCC; inhibitors; FGF; fibroblast growth factor; autocrine signaling; skin; melanoma; squamous and basal cell carcinoma; seborrheic keratosis; targeted therapy; resistance; structure; kinase inhibitor; gastric cancer; monoclonal antibody; small molecule; FGFR2c; autophagy; keratinocyte; MTOR; JNK1; review; malignant glioma; brain cancer; astrocytoma; Sprouty proteins; FGF-mediated signaling; tumor suppressor; tumor promoter; malignant pleural mesothelioma; overall survival; immunohistochemistry; infigratinib sensitivity; FGF8; FGF18; adenocarcinoma of the esophagogastric junction; neoadjuvant therapy; n/a
• Online Access: DOAB: download the publication; DOAB: description of the publication

Fibroblast growth factor (FGF) signal transmission has an essential function in embryonic development and tissue repair, and is dysregulated in the vast majority of malignancies studied. The FGF signaling in the tumor cells is usually increased by autocrine and paracrine mechanisms and gives them a high growth potential, resistance to apoptosis, neoangiogenesis and metastasis, all essential parameters relevant for tumor progression. This makes FGFs, and their tyrosine kinase receptors FGFRs, valuable targets for therapeutic interventions. This book is a collection of 15 recent articles-both original work and reviews-that summarize the current research state effectively. The content covers FGF signaling aspects in gastric, skin, liver, esophageal cancer, melanoma, mesothelioma and glioblastoma, including one article that addresses the role of FGF in the tumor-microenvironment cross-talk. Several reports describe the development of compounds targeting FGFRs, their structure and interaction with the receptor molecules, and their effectivity in preclinical and clinical testing. In summary, the papers demonstrate the complexity of the topic, with various FGF ligands and receptors involved and the need for further research. They also present results that fuel hope that targeting cancer with dysfunctional FGF signaling can become a realistic treatment option.